Candel Therapeutics Highlights Positive Clinical Progress Across Cancer Immunotherapy Pipeline in Q3 2025
ByAinvest
Thursday, Nov 13, 2025 4:35 pm ET1min read
CADL--
Candel Therapeutics reported Q3 2025 financial results and highlighted clinical progress across its cancer immunotherapy pipeline. The company presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma. Candel plans to submit a Biologics License Application for CAN-2409 in Q4 2026 and initiate a pivotal Phase 3 trial in metastatic non-squamous non-small cell lung cancer in Q2 2026. Net loss for Q3 was $11.3 million, and cash and cash equivalents totaled $87 million as of September 30, 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet